Crystal-associated rheumatic disease. Current management considerations.

Area of Science:

• Rheumatology
• Crystal-induced arthritis

Background:

• Acute crystal-associated arthropathy requires effective management strategies.
• Traditional treatments like phenylbutazone and colchicine are being re-evaluated.
• Gout management has been impacted by hypouricaemic agents, but risks exist.

Purpose of the Study:

• To review current and recommend optimal treatment approaches for crystal-associated arthropathies.
• To emphasize the importance of lifestyle modifications in gout management.
• To highlight the limitations in managing chronic pyrophosphate and hydroxyapatite diseases.

Main Methods:

• Review of existing literature on crystal-associated arthropathies.
• Comparison of traditional and modern therapeutic regimens.
• Analysis of the role of pharmacologic and non-pharmacologic interventions.

Main Results:

• Combined NSAID therapy and intra-articular steroid injections represent a modern, effective approach for acute crystal arthropathy.
• Hypouricaemic agents offer significant benefits for gout but require careful monitoring due to potential dangers.
• Dietary measures, alcohol moderation, and judicious diuretic use are essential for comprehensive gout management.
• Chronic pyrophosphate and hydroxyapatite-associated diseases currently lack disease-modifying treatments, relying on symptomatic relief.

Conclusions:

• Transitioning from older remedies to modern therapeutic combinations is advised for acute crystal arthropathy.
• A balanced approach integrating pharmacotherapy and lifestyle changes is critical for effective gout management.
• Further research is needed to develop targeted therapies for chronic pyrophosphate and hydroxyapatite-associated arthropathies.